Cogent Biosciences (COGT) Competitors $12.66 -0.15 (-1.17%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$12.70 +0.04 (+0.32%) As of 09/12/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. MRUS, CRSP, TGTX, ACAD, KRYS, CYTK, MENS, ADMA, PCVX, and AAPGShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors Merus CRISPR Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International Cogent Biosciences (NASDAQ:COGT) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Is COGT or MRUS more profitable? Cogent Biosciences has a net margin of 0.00% compared to Merus' net margin of -685.64%. Merus' return on equity of -50.28% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -223.82% -89.44% Merus -685.64%-50.28%-42.00% Do analysts prefer COGT or MRUS? Cogent Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 57.98%. Merus has a consensus price target of $88.75, indicating a potential upside of 27.55%. Given Cogent Biosciences' higher possible upside, research analysts plainly believe Cogent Biosciences is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92Merus 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has better valuation & earnings, COGT or MRUS? Merus has higher revenue and earnings than Cogent Biosciences. Merus is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$255.86M-$1.78-7.11Merus$36.13M145.65-$215.33M-$5.50-12.65 Does the media refer more to COGT or MRUS? In the previous week, Merus had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 10 mentions for Merus and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.46 beat Merus' score of 1.12 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Merus 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in COGT or MRUS? 96.1% of Merus shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by company insiders. Comparatively, 3.7% of Merus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, COGT or MRUS? Cogent Biosciences has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Merus has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. SummaryMerus beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-7.1121.5775.4626.02Price / SalesN/A254.90464.4091.13Price / CashN/A44.4425.8129.91Price / Book9.599.6112.166.25Net Income-$255.86M-$53.29M$3.29B$270.76M7 Day Performance-0.16%0.57%0.73%2.54%1 Month Performance6.48%4.56%4.41%5.73%1 Year Performance19.10%10.44%62.61%25.85% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.8799 of 5 stars$12.66-1.2%$20.00+58.0%+19.1%$1.44BN/A-7.1180Positive NewsMRUSMerus2.878 of 5 stars$65.84-0.4%$88.75+34.8%+38.8%$4.98B$36.13M-11.9737Positive NewsCRSPCRISPR Therapeutics3.2794 of 5 stars$51.83-2.3%$71.60+38.1%+15.0%$4.71B$37.31M-9.55460Positive NewsTGTXTG Therapeutics4.2988 of 5 stars$29.33+1.3%$46.25+57.7%+35.5%$4.65B$329M79.27290Positive NewsInsider TradeACADACADIA Pharmaceuticals4.375 of 5 stars$25.99-0.9%$28.88+11.1%+44.7%$4.38B$957.80M19.54510KRYSKrystal Biotech4.9236 of 5 stars$147.70-2.0%$210.38+42.4%-28.7%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.3865 of 5 stars$35.33-5.4%$71.58+102.6%-8.5%$4.23B$18.47M-6.93250Positive NewsMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageGap DownADMAADMA Biologics3.6904 of 5 stars$17.26-0.7%$27.67+60.3%-10.9%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.3331 of 5 stars$30.79+0.1%$136.50+343.3%-72.3%$4.00BN/A-7.49160Positive NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive News Related Companies and Tools Related Companies Merus Alternatives CRISPR Therapeutics Alternatives TG Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Jyong Biotech Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts